Spero Therapeutics, Inc. (SPRO)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 14,189 | 5,874 | 13,469 | |
| Restructuring | 83 | 175 | - | |
| Research and development | 10,672 | 13,606 | 26,864 | |
| General and administrative | 5,878 | 6,824 | 5,198 | |
| Total operating expenses | 16,633 | 20,605 | 32,062 | |
| Loss from operations | -2,444 | -14,731 | -18,593 | |
| Other income (expense), net | 4 | - | -26 | |
| Interest income | 740 | - | 1,182 | |
| Total other income, net | 744 | - | 1,156 | |
| Net loss before income taxes | - | - | -17,437 | |
| Income tax benefit (expense) | - | - | -290 | |
| Net loss and comprehensive loss | -1,700 | -14,731 | -17,147 | |
| Earnings per share, basic | -0.03 | -0.25 | -0.32 | |
| Earnings per share, diluted | -0.03 | -0.25 | -0.32 | |
| Weighted average number of shares outstanding, basic | 56,026,767 | 55,376,188 | 54,124,862 | |
| Weighted average number of shares outstanding, diluted | 56,026,767 | 55,376,188 | 54,124,862 | |